Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mezigdomide - Bristol-Myers Squibb

Next Previous
Drug Profile

Mezigdomide - Bristol-Myers Squibb

Alternative Names: A/I CELMoD - Bristol-Myers Squibb; BMS-986348; CC-92480; CELMoD CC-92480; Cereblon E3 Ligase Modulation Drug CC-92480; Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480; Cereblon Modulator CC-92480; MEZI

Latest Information Update: 18 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Bristol-Myers Squibb; Celgene Corporation; Johnson & Johnson; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Fluorobenzenes; Isoindoles; Nitriles; Piperazines; Piperidines; Small molecules
  • Mechanism of Action Apoptosis stimulants; CRBN protein modulators; Ubiquitin protein ligase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple myeloma
  • Phase I/II Acute myeloid leukaemia

Most Recent Events

  • 09 Mar 2026 Efficacy and adverse events data from a phase III SUCCESSOR-2 trial in Multiple myeloma released by Bristol Myers Squibb
  • 22 Jan 2026 Bristol-Myers Squibb plans a phase I trial for Acute myeloid leukemia (In adolescents, In adults, In the elderly, Second-line therapy or greater, Combination therapy) in USA (PO) in July 2026 (NCT07355335)
  • 16 Jan 2026 Phase-I/II clinical trials in Acute myeloid leukaemia (Second-line therapy or greater, In adolescents, In adults, In the elderly, Combination therapy) in USA (PO) (NCT07356154)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top